Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$821M |
| 2 |
AGN
Allergan plc
AGN
|
+$444M |
| 3 |
Apple
AAPL
|
+$304M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$301M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$839M |
| 2 |
Las Vegas Sands
LVS
|
+$405M |
| 3 |
Qualcomm
QCOM
|
+$402M |
| 4 |
Warner Bros
WBD
|
+$400M |
| 5 |
Perrigo
PRGO
|
+$357M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.61% |
| 2 | Consumer Discretionary | 14.39% |
| 3 | Communication Services | 12.98% |
| 4 | Technology | 11.5% |
| 5 | Energy | 10.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Sarepta Therapeutics
SRPT
$1.63B
| $21.6M | 0.02% |
+1,023,834
| New | +$23.1M |
|
|
CYT
427
DELISTED
CYTEC INDS INC
CYT
| $21.3M | 0.02% |
449,933
+31,505
| +8% | +$1.62M |
|
|
INFO
428
DELISTED
IHS Markit Ltd. Common Shares
INFO
| $21.2M | 0.02% |
+908,671
| New | +$23M |
|
|
INXN
429
DELISTED
Interxion Holding N.V.
INXN
| $20.8M | 0.02% |
751,209
-488,961
| -39% | -$13.5M |
|
|
KIN
430
DELISTED
Kindred Biosciences, Inc.
KIN
| $20.7M | 0.02% |
2,232,725
+725,240
| +48% | +$9.8M |
|
|
ENDP
431
CALL
DELISTED
Endo International plc
ENDP
| $20.5M | 0.02% |
300,000
| – | – |
|
|
CIM
432
Chimera Investment
CIM
$1.06B
| $20.4M | 0.02% |
446,934
-2,025
| -0.5% | -$97.5K |
|
|
DYAX
433
DELISTED
DYAX CORPORATION
DYAX
| $20.3M | 0.02% |
+2,010,562
| New | +$19.5M |
|
|
AGTC
434
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $20.2M | 0.02% |
1,084,520
+375,513
| +53% | +$6.8M |
|
435
Commault Systems
CVLT
$4.97B
| $19.9M | 0.02% |
394,932
+23,913
| +6% | +$1.23M |
|
|
MDCO
436
DELISTED
Medicines Co
MDCO
| $19.7M | 0.02% |
881,454
+1,317
| +0.1% | +$33.4K |
|
437
UnitedHealth
UNH
$389B
| $19.6M | 0.02% |
226,911
-425,576
| -65% | -$36M |
|
|
SGMO
438
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $19.1M | 0.02% |
1,768,392
-89,426
| -5% | -$1.17M |
|
|
HMHC
439
DELISTED
Houghton Mifflin Harcourt Company
HMHC
| $18.3M | 0.02% |
943,612
+60,807
| +7% | +$1.14M |
|
440
NN Inc
NNBR
$261M
| $18M | 0.02% |
672,281
+330,667
| +97% | +$9.09M |
|
441
Mercado Libre
MELI
$94.4B
| $17.9M | 0.02% |
+164,531
| New | +$17.1M |
|
|
LMOS
442
DELISTED
Lumos Networks Corp
LMOS
| $17.8M | 0.02% |
1,093,484
-342,643
| -24% | -$5.07M |
|
|
PKY
443
DELISTED
Parkway, Inc.
PKY
| $17.6M | 0.02% |
938,412
+130,164
| +16% | +$2.66M |
|
444
Prothena Corp
PRTA
$448M
| $17.5M | 0.02% |
790,179
-84,615
| -10% | -$1.79M |
|
|
PFPT
445
DELISTED
Proofpoint, Inc.
PFPT
| $17.1M | 0.02% |
460,022
+109,991
| +31% | +$4.1M |
|
446
Tandem Diabetes Care
TNDM
$1.22B
| $17.1M | 0.02% |
127,204
+5,268
| +4% | +$738K |
|
447
PUT
Biogen
BIIB
$30.4B
| $17.1M | 0.02% |
+51,600
| New | +$17M |
|
448
CALL
Bausch Health
BHC
$1.69B
| $17.1M | 0.02% |
130,000
| – | – |
|
|
ORBC
449
DELISTED
ORBCOMM, Inc.
ORBC
| $16.4M | 0.02% |
2,843,639
+187,128
| +7% | +$1.17M |
|
450
Huron Consulting
HURN
$1.97B
| $16.3M | 0.02% |
267,419
-145,592
| -35% | -$9.3M |
|
Similar funds
Jennison Associates's Q3 2014 Portfolio in Review
As of Q3 2014, Jennison Associates held 788 positions worth $108B, down 0.96% from $109B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jennison Associates's Q3 2014 filing shows 82 new, 334 increased, 281 reduced and 71 closed positions. Its largest new stake was Alibaba: 9,140,584 shares worth $812M. The largest sale was RTX Corp, an estimated $839M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q3 2014 buy was Alibaba: 9,140,584 shares worth $812M.
- Jennison Associates added most to Allergan plc in Q3 2014, an estimated $444M increase.
- Jennison Associates's biggest Q3 2014 reduction was Las Vegas Sands, cutting an estimated $405M.
- Jennison Associates fully exited RTX Corp in Q3 2014, selling an estimated $839M.
- Jennison Associates's ten largest holdings make up 20% of its $108B portfolio in Q3 2014.
- Jennison Associates opened 82 new positions and closed 71 in Q3 2014.
- Jennison Associates's portfolio value fell 0.96% quarter-over-quarter to $108B.
Based on Jennison Associates's 13F filing for Q3 2014, filed 5 Nov 2014.